

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 July 2025 (03.07.2025)



(10) International Publication Number
WO 2025/144931 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 413/14 (2006.01)
C07D 403/04 (2006.01) C07D 417/14 (2006.01)
C07D 403/14 (2006.01) C07D 471/04 (2006.01)
C07D 405/04 (2006.01) C07D 487/10 (2006.01)
C07D 405/14 (2006.01) A61P 35/00 (2006.01)
C07D 409/04 (2006.01) A61K 31/4709 (2006.01)
C07D 409/14 (2006.01)

(21) International Application Number:

PCT/US2024/061954

(22) International Filing Date:

26 December 2024 (26.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/615,064 27 December 2023 (27.12.2023) US
63/675,810 26 July 2024 (26.07.2024) US

(71) Applicant: GENESIS THERAPEUTICS, INC. [US/US];
1440 Chapin Avenue, Suite 385, Burlingame, CA 94010
(US).

(72) Inventors: BUSCH, Brett; 1440 Chapin Avenue, Suite
385, Burlingame, CA 94010 (US). REINUS, Brandon;
1440 Chapin Avenue, Suite 385, Burlingame, CA 94010
(US). INDARTE, Martin; 1440 Chapin Avenue, Suite
385, Burlingame, CA 94010 (US). MCALPINE, In-
drawan; 1440 Chapin Avenue, Suite 385, Burlingame, CA
94010 (US). KAGIN, Zachary Joseph; 1440 Chapin Av-
enue, Suite 385, Burlingame, CA 94010 (US). VERNIER,
William, F.; 1440 Chapin Avenue, Suite 385, Burlingame,
CA 94010 (US).

(74) Agent: BATES, Caleb, A. et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR TREATING CANCER

(57) Abstract: This disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit phos-
phatidylinositol 4,5-bisphosphate 3 kinase (PI3K) isoform alpha (PI3K α). These compounds are useful for treating a disease in which
increased PI3K α activation contributes to the pathology, symptoms, and/or progression of the disease (e.g., cancer) in a subject.

WO 2025/144931 A1